journal article·2023-08-25Open access

Role of the Lactide:Glycolide Ratio in PLGA Nanoparticle Stability and Release under Lysosomal Conditions for Enzyme Replacement Therapy of Lysosomal Storage Disorders

Maria del Moral, Maximilian Loeck, Eameema Muntimadugu, Guillem Vives, Vy Pham, Peter Pfeifer, Giuseppe Battaglia, Silvia Muro

Abstract

Prior studies demonstrated that encapsulation in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) enhanced the delivery of enzymes used for replacement therapy (ERT) of lysosomal storage disorders (LSDs). This study examined how the copolymer lactide:glycolide ratio impacts encapsulation, physicochemical characteristics, stability, and release under lysosomal conditions. Hyaluronidase, deficient in mucopolysaccharidosis IX, was encapsulated in NPs synthesized using 50:50, 60:40, or 75:25 lactide:glycolide copolymers. All NPs had diameters compatible with cellular transport (≤168 nm) and polydispersity indexes (≤0.16) and ζ-potentials (≤−35 mV) compatible with colloidal stability. Yet, their encapsulation efficiency varied, with 75:25 NPs and 60:40 NPs having the lowest and highest EE, respectively (15% vs. 28%). Under lysosomal conditions, the 50:50 copolymer degraded fastest (41% in 1 week), as expected, and the presence of a targeting antibody coat did not alter this result. Additionally, 60:40 NPs destabilized fastest (<1 week) because of their smaller diameter, and 75:25 NPs did not destabilize in 4 weeks. All formulations presented burst release under lysosomal conditions (56–78% of the original load within 30 min), with 50:50 and 60:40 NPs releasing an additional small fraction after week 1. This provided 4 weeks of sustained catalytic activity, sufficient to fully degrade a substrate. Altogether, the 60:40 NP formulation is preferred given its higher EE, and 50:50 NPs represent a valid alternative, while the highest stability of 75:25 NPs may impair lysosomes. These results can guide future studies aiming to translate PLGA NP-based ERT for this and other LSDs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Lysosomal Storage Disorders Research · Pineapple and bromelain studies · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute for Science and Technology, 08028 Barcelona, Spain

Applied Materials Chemistry Master Program (M.d.M) and Biomedicine Doctorate Program, University of Barcelona, 08007 Barcelona, Spain

Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA

Nanoscience and Nanotechnology Degree Program, Autonomous University of Barcelona, 08193 Bellaterra, Spain

Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, MD 20742, USA

Institution of Catalonia for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain

Funding

Spanish Ministry of Science and Innovation · “ERDF A way of making Europe” · Generalitat de Catalunya · National Institutes of Health · INPhINIT Predoctoral Fellowship · Fundación La Caixa and Horizon 2020 Marie Sklodowska-Curie · Master Fellowship · H2020-ERC-2018-CoG CheSSTaG

References (74)

Show source-provided references
1. Lysosomes: Fusion and function10.1038/nrm2217 ↗
2. Lysosome: The metabolic signaling hub10.1111/tra.12617 ↗
4. Role of lysosomes in physiological activities, diseases, and therapy10.1186/s13045-021-01087-1 ↗
5. Targeting lysosomes in human disease: From basic research to clinical applications10.1038/s41392-021-00778-y ↗
6. Lysosomes as a therapeutic target10.1038/s41573-019-0036-1 ↗
7. The cell biology of lysosomal storage disorders10.1038/nrm1423 ↗
8. Lysosomal storage disorders10.1038/s41572-018-0025-4 ↗
9. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease10.1007/BF00710267 ↗
10. Variable clinical presentation in lysosomal storage disorders10.1023/A:1012463605992 ↗
11. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders10.1007/s13346-012-0072-4 ↗
12. Therapy for lysosomal storage disorders10.1002/iub.284 ↗
13. Limitations of enzyme replacement therapy: Current and future10.1007/s10545-006-0239-6 ↗
14. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities10.1016/j.pharmthera.2004.08.001 ↗
15. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins10.1016/j.addr.2022.114234 ↗
16. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders10.1016/j.addr.2022.114464 ↗
17. Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders10.1016/j.addr.2022.114465 ↗
18. Liposomal formulations for treating lysosomal storage disorders10.1016/j.addr.2022.114531 ↗
19. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders10.1016/j.addr.2022.114683 ↗
20. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date10.1007/s11095-016-1958-5 ↗
21. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
22. Emerging methods for the fabrication of polymer capsules10.1016/j.cis.2013.10.012 ↗
23. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices10.1016/S0142-9612(00)00115-0 ↗
24. Synthesis and characterization of PLGA nanoparticles10.1163/156856206775997322 ↗
25. Suggested Procedures for the Reproducible Synthesis of Poly(d,l-lactide-co-glycolide) Nanoparticles Using the Emulsification Solvent Diffusion Platform10.2174/1573413714666180313130235 ↗
26. Biodegradation and biocompatibility of PLA and PLGA microspheres10.1016/S0169-409X(97)00048-3 ↗
27. FDA’s poly (lactic-co-glycolic acid) research program and regulatory outcomes10.1208/s12248-021-00611-y ↗
28. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases10.1080/15548627.2015.1136769 ↗
29. Harnessing lysosomal pH through PLGA nanoemulsion as a treatment of lysosomal-related neurodegenerative diseases10.1021/acs.bioconjchem.8b00697 ↗
30. Biodegradable PLGA Nanoparticles Restore Lysosomal Acidity and Protect Neural PC-12 Cells against Mitochondrial Toxicity10.1021/acs.iecr.9b02003 ↗
31. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme10.1016/j.jconrel.2020.05.009 ↗
32. Muntimadugu, E., Silva-Abreu, M., Vives, G., Loeck, M., Pham, V., Del Moral, M., Solomon, M., and Muro, S. (2022). Comparison between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy. Int. J. Mol. Sci., 23.10.3390/ijms23074034 ↗
33. Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases10.1016/j.jconrel.2022.07.022 ↗
34. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice10.1016/j.ymthe.2017.05.014 ↗
35. Cross-linked enzyme aggregates as versatile tool for enzyme delivery: Application to polymeric nanoparticles10.1021/acs.bioconjchem.8b00206 ↗
36. Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease10.1126/sciadv.aax7462 ↗
37. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier10.1016/j.jconrel.2005.07.013 ↗
38. Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M.A., Forni, F., and Scarpa, M. (2016). Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE, 11.10.1371/journal.pone.0156452 ↗
39. Rigon, L., Salvalaio, M., Pederzoli, F., Legnini, E., Duskey, J.T., D’Avanzo, F., De Filippis, C., Ruozi, B., Marin, O., and Vandelli, M.A. (2019). Targeting brain disease in MPSII: Preclinical evaluation of IDS-loaded PLGA nanoparticles. Int. J. Mol. Sci., 20.10.3390/ijms20082014 ↗
40. Brain-targeted polymeric nanoparticles: In vivo evidence of different routes of administration in rodents10.2217/nnm.12.172 ↗
41. Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts10.1166/jnn.2015.9251 ↗
42. Drug Release Kinetics and Transport Mechanisms of Non-degradable and Degradable Polymeric Delivery Systems10.1517/17425241003602259 ↗
43. Degradation of poly(lactic-co-glycolic acid) microspheres: Effect of copolymer composition10.1016/0142-9612(95)93575-X ↗
44. Biodegradation of PLA/GA polymers: Increasing complexity10.1016/0142-9612(94)90271-2 ↗
45. Investigation of factors influencing the hydrolytic degradation of single PLGA microparticles10.1016/j.polymdegradstab.2015.04.025 ↗
46. A novel approach to monitor intracellular degradation kinetics of poly(lactide-co-glycolide) nanoparticles by means of flow cytometry10.1039/C3TB21330G ↗
47. Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories10.1002/jbm.b.33648 ↗
48. Clinical and biochemical manifestations of hyaluronidase deficiency10.1056/NEJM199610033351405 ↗
49. A complete deficiency of Hyaluronoglucosaminidase 1(HYAL1) presenting as familial juvenile idiopathic arthritis10.1007/s10545-011-9343-3 ↗
50. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX10.1073/pnas.96.11.6296 ↗
51. Antibody adsorption and orientation on hydrophobic surfaces10.1021/la203095p ↗
52. Zeta Potential and Colloidal Stability Predictions for Inorganic Nanoparticle Dispersions: Effects of Experimental Conditions and Electrokinetic Models on the Interpretation of Results10.1021/acs.langmuir.1c02056 ↗
53. Colloidal stability as a determinant of nanoparticle behavior in the brain10.1016/j.colsurfb.2018.06.050 ↗
54. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-110.1242/jcs.00367 ↗
55. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers10.1038/mt.2008.127 ↗
56. Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium10.1161/ATVBAHA.111.244186 ↗
57. Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting10.1021/nn404719c ↗
58. Caveolae: From basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo10.1016/S0169-409X(01)00141-7 ↗
59. Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin10.1016/j.jconrel.2017.12.025 ↗
60. Current developments and applications of microfluidic technology toward clinical translation of nanomedicines10.1016/j.addr.2017.08.003 ↗
61. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer10.1021/nn501371n ↗
62. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method
63. Effect of acidic and basic environment to the degradation behavior of PLGA nanocapcules for biomedical application10.4028/www.scientific.net/AMR.1123.213 ↗
64. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer10.1080/10717544.2021.1958106 ↗
65. In-vitro degradation of PLGA nanoparticles in aqueous medium and in stem cell cultures by monitoring the cargo fluorescence spectrum10.1016/j.polymdegradstab.2016.10.017 ↗
66. Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration10.1021/mp300559v ↗
67. Pore change during degradation of octreotide acetate-loaded PLGA microspheres: The effect of polymer blends10.1016/j.ejps.2019.104990 ↗
68. Antibody stability: A key to performance—Analysis, influences and improvement10.1016/j.biochi.2020.08.019 ↗
69. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies10.1002/prot.21243 ↗
70. Phenomenology of the Initial Burst Release of Drugs from PLGA Microparticles10.1021/acsbiomaterials.0c01228 ↗
71. Chemical and spatial analysis of protein loaded PLGA microspheres for drug delivery applications10.1016/j.jconrel.2012.05.008 ↗
72. Benita, S. (2006). Microencapsulation Methods and Industrial Applications, Taylor & Francis.
73. A method to improve quantitative radiotracing-based analysis of the in vivo biodistribution of drug carriers10.1002/btm2.10208 ↗
74. Protein instability toward organic solvent/water emulsification: Implications for protein microencapsulation into microspheres. P.D.A